11 / 24
Page 68
conferenceseries
.com
Volume 7
OMICS Journal of Radiology
Radiology and Oncology 2018
July 16-17, 2018
July 16-17, 2018 Dubai, UAE
Radiology and Oncology
2
nd
World Congress on
Assessment of Ga-68 prostate specific membrane antigen progress using PET/CT in patients with
prostate cancer
Habibollah Dadgar
Imam Reza International University, Iran
P
rostate cancer is one of the most malignancies affecting men. Recurrence of prostate cancer is usually assessed by elevating
serumProstate-Specific Antigen (PSA) level. These days, new radiotracers using Positron Emission Tomography (PET) have
demonstrated new insights recurrence of disease. Meanwhile, emerging Ga-68 Prostate Specific Membrane Antigen (PSMA)
provides opportunities to localize prostate cancer in low level of PSA and recurrence. In the current report we presented intense
uptake in Ga-68 PSMA, (PET)/Computed Tomography (CT) in early and late monitoring of 74 years old male patient with
prostate carcinoma diagnoses. An automated synthesis module (Scintomics GRP, Fürstenfeldbruck, Germany) and 68-Ge/68-
Ga generator (Pars Isotope, Tehran, Iran) used for radio-pharmaceutical production was purchased. Disposable cassette kits
and chemicals including the precursor DKFZ-PSMA-11 were obtained from ABX advanced biochemical compounds. A HPLC
system was used to determine the radiochemical purity. Radionuclidic purity of the final product solution and separation
cartridges was analyzed using gamma spectrometry. Fast radio-labeling of HBED-CC represents which this radiopharmaceutical
is a stable at room temperature. Stability procedures controlled with distinct temperature conditions during the radio-labeling
reaction and directed predominantly to the formation of the thermodynamically more stable one. 68Ga-PSMA-HBED-CC
(68Ga-PSMA-11) radio-synthesis implemented using a cassette-based procedure. Clinical 68Ga-PSMA-HBED-CC PET/CT
scanning resulted in high quality images in patients. 68Ga-PSMA-11 is a promising radiotracer in which has better sensitivity
and specificity for even low level of prostate cancer lesions versus the conventional imaging.
reza.lt.dadgar@gmail.comOMICS J Radiol 2018, Volume 7
DOI: 10.4172/2167-7964-C1-022